Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics

用于控制药代动力学的下一代肠外给药系统

• 批准号: 10277139
• 负责人: Kevin James McHugh
• 金额: $ 38.42万
• 依托单位: RICE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10277139
• 关键词: 3D Print; Acute; Area; Behavior; Biocompatible Materials; Biological; Chemistry; Chronic; Chronic Disease; Clinical; Complex; Disease; Dose; Drug Delivery Systems; Drug Kinetics; Encapsulated; Exhibits; FDA approved; Formulation; Frequencies; Geometry; Goals; Half-Life; Health Care Costs; Hydrophobicity; Injectable; Kinetics; Medicine; Methods; Modeling; Morbidity - disease rate; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Pharmacy (field); Polymers; Regimen; Route; Running; Safety; Site; Structure; Structure-Activity Relationship; Surface; System; Therapeutic; Water; compliance behavior; controlled release; design; drug release kinetics; improved; interest; mortality; multi-photon; nanofabrication; next generation; particle; prevent; side effect; therapy duration; welfare

PROJECT SUMMARY/ABSTRACT Every day, an estimated 3.9 billion people take medication to treat acute or chronic conditions. However, despite the enormous utility of current pharmaceuticals, they are limited by several factors that prevent their more effective and expanded use. Ideally, drugs would reach the desired concentration at the site of action for the duration that the therapy is required. In practice, this is difficult because the body is constantly metabolizing and excreting drugs, which necessitates re-administration. Depending on a drug’s therapeutic window and biological half-life, frequent administration may be required, which lowers patients’ adherence to their dosing regimens. This issue is pervasive with non-adherence rates as high as 50% for chronic diseases, leading to increased morbidity and mortality and as much as $290 billion in added healthcare costs each year in the U.S. alone. The field of pharmaceutics has developed formulation methods that reduce administration frequency, including injectable controlled-release systems composed of drug embedded in biodegradable materials. Unfortunately, current clinically-approved systems are limited in both the types of molecules that they can deliver and the drug release kinetics they can achieve. This proposal seeks to develop parenteral drug delivery strategies that enhance safety and efficacy, improve patient adherence, and enable the sustained release of biological drugs. We hypothesize that emerging nanofabrication methods (e.g. multi-photon 3D printing) can be used to control the structure—and thus behavior—of surface-eroding particles containing drug. Because the degradation of these hydrophobic materials is confined to the surface, drug distributed homogeneously throughout their volume will be released at a rate proportional to their erosion rate and exposed surface area. Using these methods, we can model and rationally design microparticle structures that release drug at predictable, geometrically-defined rates. Although this concept could be applied to achieve a wide array of release kinetics, we are most interested in attaining zero-order release kinetics, which are desirable for most diseases, and sequential release, which may be useful for dynamic conditions. Further, because surface eroding materials exclude water, their interior microenvironment will remain dry and neutral, thus promoting the stability of encapsulated biologics at 37°C. The features of surface-eroding microparticles run in stark contrast with existing FDA-approved microparticles composed of bulk-degrading polymers that absorb water and produce acidic degradation products, which makes it impossible to predict release kinetics a priori, contributes to the degradation of encapsulated biologics, and prevents sequential release. The strategies we propose are only now possible due to the convergence of advances in manufacturing and chemistry that allow us to exploit structure-function relationships at a scale small enough to retain microparticle injectability. If successful, this approach has the ability to fundamentally change how drugs are administered and improve patient outcomes across all of medicine.

项目摘要/摘要 据估计，每天有39亿人服用药物治疗急性或慢性病。然而，尽管 当前药物的巨大效用，它们受到几个因素的限制，这些因素阻止了它们更多的 有效和扩大使用。理想情况下，药物会在作用部位达到理想的浓度 需要治疗的持续时间。在实践中，这是困难的，因为身体不断地代谢和 排泄药物，这需要重新给药。取决于药物的治疗窗口和生物学特性 可能需要半衰期，经常给药，这会降低患者对剂量方案的依从性。 这个问题很普遍，慢性病的不依从率高达50%，导致 发病率和死亡率，仅在美国每年增加的医疗成本就高达2900亿美元。这个 药剂学领域已经开发出减少给药频率的配方方法，包括 由植入生物可降解材料中的药物组成的可注射控制释放系统。不幸的是， 目前临床批准的系统在它们可以传递的分子类型和药物方面都受到限制。 他们能达到的释放动力学。该提案寻求开发非肠道给药策略，以 增强安全性和有效性，提高患者依从性，使生物药物能够持续释放。 我们假设新兴的纳米制造方法(例如多光子3D打印)可以用来控制 含有药物的表面侵蚀颗粒的结构--以及由此产生的行为。因为生物多样性的退化 这些疏水材料被限制在表面，药物在其体积中均匀分布 将以与其腐蚀率和裸露表面积成正比的速度释放。使用这些方法，我们 可以模拟和合理设计微粒子结构，以可预测的、几何定义的方式释放药物 费率。虽然这一概念可以应用于实现广泛的释放动力学，但我们最感兴趣的是 在获得大多数疾病所需的零级释放动力学和顺序释放中，所述顺序释放 可能对动态条件有用。此外，由于表面侵蚀材料不含水，它们的内部 微环境将保持干燥和中性，从而促进微囊化生物制剂在37℃下的稳定性。 表面侵蚀微粒的特征与现有FDA批准的微粒形成鲜明对比 由大量可降解的聚合物组成，可吸收水分并产生酸性降解产物，这使得 不可能事先预测释放动力学，这会导致被包裹的生物制品的降解，并且 防止顺序释放。我们提出的战略现在才有可能，因为 制造和化学方面的进展，使我们能够在小范围内开发结构-功能关系 足以保持微粒的可注入性。如果成功，这种方法将有能力从根本上改变 如何给药并改善所有医学领域的患者结果。